High-Risk Genotypes of Human Papillomavirus at Diverse Anogenital Sites among Chinese Women: Infection Features and Potential Correlation with Cervical Intraepithelial Neoplasia

• Published in: Cancers Vol. 16; no. 11; p. 2107
• Main Authors: Zhao, Chao, An, Jiahui, Li, Mingzhu, Li, Jingran, Zhao, Yun, Wang, Jianliu, Xie, Heidi Qunhui, Wei, Lihui
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 31.05.2024; MDPI
• Subjects: Anogenital; Anus; Cancer; Cancer therapies; Cellular biology; Cervical cancer; Cervix; Cervix dysplasia; Complications and side effects; Diagnosis; Females; Genotype; Genotypes; Genotyping; high-risk human papillomavirus (HR-HPV); Human papillomavirus; Infections; Lesions; Medical screening; Oncology, Experimental; Papillomavirus infections; Pathology; prevalence; Risk factors; Vagina; Vulva; China; United States > US; prevalence; high-risk human papillomavirus (HR-HPV); anogenital; cervical cancer
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16112107

Both cervical cancer and cervical intraepithelial neoplasia (CIN) are associated with human papillomavirus (HPV) infection at different anogenital sites, but the infection features of high-risk (HR) HPVs at these sites and their association with cervical lesions have not been well characterized. Given the limitation of cervical HPV 16/18 test in screening patients with high-grade CIN (CIN 2+), studies on whether non-16/18 HR-HPV subtype(s) have potential as additional indicator(s) to improve CIN 2+ screening are needed. The infection of 15 HR-HPVs in vulva, anus, vagina, and cervix of 499 Chinese women was analyzed, and CIN lesion-associated HR-HPV subtypes were revealed. In addition to the well-known cervical-cancer-associated HPV 16, 52, and 58, HPV 51, 53, and 56 were also identified as high-frequency detected subtypes prevalently and consistently present at the anogenital sites studied, preferentially in multi-infection patterns. HPV 16, 52, 58, 56, and 53 were the top five prevalent subtypes in patients with CIN 2+. In addition, we found that cervical HPV 33/35/52/53/56/58 co-testing with HPV 16/18 might improve CIN 2+ screening performance. This study provided a new insight into HR-HPV screening strategy based on different subtype combinations, which might be used in risk stratification clinically.